Abstract
While alterations in the gut microbiota have long been linked to hypertension, the role of archaea—stable yet often overlooked constituents of the human microbiome—remains largely unexplored. This study utilized shotgun metagenomic analysis of fecal samples from 341 participants across three distinct cohorts (Discovery, Validation 1, and Validation 2) to characterize the enteric archaeome in hypertensive patients. Principal Coordinates Analysis (PCoA) revealed significant shifts in archaeal composition between healthy controls and hypertensive individuals. Specifically, hypertensive groups exhibited a marked depletion of halophilic and methanogenic archaea. A diagnostic panel of 11 archaeal species demonstrated high accuracy in distinguishing hypertensive patients, with AUC values ranging from 0.79 to 0.91. Furthermore, significant correlations between archaeal richness and bacterial richness suggest a cross-kingdom synergy that is disrupted in disease states. These findings underscore the potential of archaeal biomarkers for hypertension diagnosis and suggest new avenues for therapeutic intervention.
Introduction
Hypertension is a primary driver of cardiovascular disease globally, yet its etiology involves complex interactions between genetics, environment, and the microbiome. While the "gut-heart axis" has gained significant attention, research has focused almost exclusively on the bacterial domain. Archaea, the third domain of life, are essential and stable members of the human gut, yet their contribution to cardiovascular health has remained a "dark matter" in metagenomic research. This study aims to bridge this gap by investigating whether gut archaea composition shifts in hypertensive patients and how these microbes interact with their bacterial counterparts.
Methodology and Cohort Design
The researchers employed a robust multi-cohort design to ensure the generalizability of their findings:
- Discovery Cohort (n=88): Sourced from Dalian, China.
- Validation Cohort 1 (n=175): Sourced from Tangshan, China, including healthy, pre-hypertensive (pHTN), and hypertensive individuals.
- Validation Cohort 2 (n=78): An in-house cohort from Fuwai Hospital, Beijing.
Shotgun metagenomic sequencing was performed on fecal samples, with taxonomic profiling conducted via MetaPhlAn3. The team analyzed Alpha diversity (Shannon and Chao1 indices) and Beta diversity (Bray-Curtis distances). To explore the diagnostic potential of the archaeome, a logistic regression model was developed to identify a biomarker panel. Finally, the SparCC algorithm was used to map cross-kingdom interactions between archaea and bacteria.
Key Findings
The Depletion of Beneficial Archaea
The study found that hypertension is characterized not by the invasion of pathogenic archaea, but by the significant loss of specific beneficial taxa. Hypertensive patients showed a marked reduction in:
- Halophilic Archaea: Including Halorhabdus, Halovivax, and Halorubrum lipolyticum.
- Methanogenic Archaea: Specifically Methanomassiliicoccus and Candidatus Methanomassiliicoccus intestinalis.
Interestingly, these shifts were detectable even in the pre-hypertension (pHTN) phase, suggesting that archaeal dysbiosis occurs early in the progression of high blood pressure.
Diagnostic Performance
The researchers identified a signature of 11 archaeal species depleted in hypertensive patients. This panel proved to be a highly effective diagnostic tool, achieving Areas Under the Curve (AUC) of 0.85 in the discovery cohort, 0.79 in validation cohort 1, and 0.91 in validation cohort 2. All 11 markers showed significant negative correlations with both Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP).
Cross-Kingdom Synergy and the TMAO Hypothesis
A significant positive correlation was observed between bacterial and archaeal richness, suggesting a symbiotic relationship. However, the interaction network became more complex and potentially "stressed" in hypertensive patients, with an increased number of correlation nodes compared to healthy controls.
Functional analysis suggests a metabolic link involving Trimethylamine (TMA). Certain methanogenic archaea utilize TMA—a precursor to the pro-atherogenic compound Trimethylamine N-oxide (TMAO)—as a substrate. The depletion of these archaea in hypertensive patients may result in a lost "filter," allowing TMA to be converted into TMAO, which is known to increase vascular tension and contribute to hypertension.
Discussion and Future Directions
This research provides a new perspective on the gut-heart axis by highlighting the diagnostic and functional importance of the enteric archaeome. The high AUC values across multiple cohorts suggest that archaeal signatures could serve as reliable biomarkers for hypertension.
However, the study is limited by its cross-sectional nature, which establishes correlation rather than causation. It remains to be determined whether the loss of these archaea is a cause or a consequence of the hypertensive state. Future research should prioritize:
- Longitudinal Studies: To determine the temporal relationship between archaeal shifts and blood pressure elevation.
- Interventional Trials: To explore "archaeobiotics"—the use of specific archaea to restore microbial balance and potentially lower blood pressure.
- Mechanistic Studies: To confirm the role of archaea in modulating TMA/TMAO levels and other metabolic pathways relevant to cardiovascular health.
Summary updated